Nocion Therapeutics has announced that it raised $62 million in a Series B funding led by Monograph Capital and Arkin Bio Capital. Proceeds will be used to support a Phase 2b trial of its taplucainium (NTX-1175) inhaled dry powder for the treatment of chronic cough, the company said.
In January 2020, Pulmatrix said that it had signed a deal to evaluate the use of its iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. In August 2021, Nocion announced the initiation of a Phase 2a trial of a nebulized formulation of NTX-1175 in patients with chronic cough.
Nocion CEO Richard Batycky commented, “We are grateful to our new and existing investors for their commitment to our lead program in this challenging disease. This financing will enable us to evaluate taplucainium in patients suffering from chronic cough. We will also be able to conduct additional toxicology and product development activities with an eye towards being ready for Phase 3 clinical trials.”
Read the Nocion Therapeutics press release.
